Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161368 | 0.84 | GRM7 (0.48) | KDM1A | |
| SCHEMBL5158967 | 0.80 | MAPT (0.48) | PTGS1PTGS2CYP2C9HPGDLMNA | |
| SCHEMBL5158320 | 0.78 | KMT2A (0.51) | HPGDLMNAALDH1A1 | |
| SCHEMBL6481046 | 0.76 | SSTR4 (0.40) | KDM1A | |
| SCHEMBL5202490 | 0.75 | HPGD (0.42) | PTGS1PTGS2CYP2C9HPGDLMNA | |
| SCHEMBL5161850 | 0.73 | KDM1A (0.43) | KDM1A | |
| SCHEMBL5161860 | 0.73 | MAPT (0.47) | ALDH1A1KDM1A | |
| SCHEMBL5156707 | 0.72 | KDM1A (0.47) | KDM1A | |
| SCHEMBL5202478 | 0.72 | HPGDS (0.41) | PTGS1PTGS2CYP2C9HPGDLMNA | |
| SCHEMBL6493783 | 0.72 | GRM7 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| EP-1301497-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004434-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | PTGS1 929/4885PTGS2 1321/4885CYP2C9 3981/4885 |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | TOP1, TDP1, TOP2B | PTGS1 565/4885PTGS2 2000/4885CYP2C9 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.